Canadian researchers have published a new study in the journal of biological chemistry a previously hidden channel attack discovered leukemia and other cancer cells. The conclusions of the Université de Montreal and Universite Laval Hôpital Maisonneuve-Rosemont can handle doctors change patients with cancer.
"We found a gateway, which is in all people people who thereby reach the Bleomycin anti-cancer agents, so that they can attack penetrate the leukemia cells in the body," said connected main author Dindial Ramotar, Professor at the Faculty of the University of Montreal and scientists of the Maisonneuve-Rosemont Hospital.
Dr. Ramotar started, to test his theory, ten years ago with the yeast for Baker, the human cells remarkably similar to is. "Our discovery of this system of the model of to human cells and will soon reach bedside by translational therapy," he explains. "We are patients at the edge of the test."
The new gateway (SLC22A16) can be a lifesaver for patients with acute myeloid leukemia (AML), cancer, which affects white blood cells. AML patients are very difficult to treat because the most insensitive to anti-cancer drugs. "We can now optimize anti cancer agent AML, treat", explains Dr. Ramotar. "For example, we found the agent cancer drug Bleomycin has derived positive results on lymphoma cells from patients and depends on the presence of the bridge." This is particularly pleasing, Bleomycin as no immunosuppressant. »
The newly identified, Dr. Ramotar gateway is warnings, not the "in certain cells such as those from the bone marrow." The channel also doesn't work in cancer of colorectal and breast cancer, it makes added these patients with Bleomycin difficult. "Now we must stimulate the gateway to handle a variety of cancers with Bleomycin and other drugs check."
Partners in research:
This study was financed of health of cancer Canada Research and the National Institute of the Canadian Institute.
About the study:
The book, "the human carnitine carrier SLC22A16 inclusion of the anti-cancer polyamines conveys Bleomycin-A5, high affinity analog" published in Journal of biological chemistry, Mustapha Aouida and Dindial Ramotar from the University of Montreal, in collaboration with Richard Poulin, Université Laval wrote.